About Entasis Therapeutics
Entasis Therapeutics is a company based in Waltham (United States) founded in 2015 was acquired by Innoviva in May 2022.. Entasis Therapeutics has raised $121.9 million across 5 funding rounds from investors including Astrazeneca, Blackstone and TPG. The company has 40 employees as of December 31, 2022. Entasis Therapeutics offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. Entasis Therapeutics operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Waltham, United States
- Employees 40 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Innoviva Specialty Therapeutics
-
Annual Revenue
$7 M40as on Dec 31, 2019
-
Net Profit
-
EBITDA
-
Total Equity Funding
$121.9 M (USD)
in 5 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Aug 28, 2020
-
Investors
Astrazeneca
& 8 more
-
Employee Count
40
as on Dec 31, 2022
-
Acquired by
Innoviva
(May 23, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Entasis Therapeutics
Entasis Therapeutics offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats critical care conditions like low blood pressure.
Fights serious bacterial infections in hospitalized patients.
Addresses infections caused by drug-resistant microorganisms.
Targets uncomplicated gonorrhea infections in clinical development.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Entasis Therapeutics
Entasis Therapeutics has successfully raised a total of $121.9M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(01 Mar 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Post-IPO - Entasis Therapeutics | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Entasis Therapeutics | Valuation |
investors |
|
| Sep, 2017 | Amount | Series B - Entasis Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Entasis Therapeutics
Entasis Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Blackstone and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Entasis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Entasis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Entasis Therapeutics Comparisons
Competitors of Entasis Therapeutics
Entasis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Entasis Therapeutics
Frequently Asked Questions about Entasis Therapeutics
When was Entasis Therapeutics founded?
Entasis Therapeutics was founded in 2015.
Where is Entasis Therapeutics located?
Entasis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Entasis Therapeutics a funded company?
Entasis Therapeutics is a funded company, having raised a total of $121.9M across 5 funding rounds to date. The company's 1st funding round was a Series B of $31.9M, raised on Mar 01, 2015.
How many employees does Entasis Therapeutics have?
As of Dec 31, 2022, the latest employee count at Entasis Therapeutics is 40.
What is the annual revenue of Entasis Therapeutics?
Annual revenue of Entasis Therapeutics is $7M as on Dec 31, 2019.
What does Entasis Therapeutics do?
Entasis Therapeutics was founded in 2015 and is based in Waltham, United States, within the biotechnology sector. Focus is placed on developing small-molecule antibiotics targeting multidrug-resistant Gram-negative infections, such as those caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. A single-dose oral therapy for both susceptible and resistant Neisseria gonorrhoeae is also pursued. The lead candidate, ETX0914, is advanced as an oral antibiotic for uncomplicated gonorrhea treatment.
Who are the top competitors of Entasis Therapeutics?
Entasis Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does Entasis Therapeutics offer?
Entasis Therapeutics offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Who are Entasis Therapeutics's investors?
Entasis Therapeutics has 9 investors. Key investors include Astrazeneca, Blackstone, TPG, Innoviva, and Frazier Healthcare Partners.